navitoclax
Small moleculeexperimental
Navitoclax is an experimental orally active anti-cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. — Wikipedia
Clinical trial activity
45 trials · 31 clinical orgs · 0 marketing orgs
Phase 1
30
Phase 2
22
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00406809)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Fibrosis · Phase 1
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 1
- Hepatitis B · Phase 1
- Hepatitis C, Chronic · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Lymphoid · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 2
- Melanoma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Primary Myelofibrosis · Phase 3
- Prostatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).
Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w.
- Apoptosis regulator Bcl-XINHIBITOR
BCL2L1 inhibitor
High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).
Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w.
- Apoptosis regulator Bcl-WINHIBITOR
BCL2L2 inhibitor
High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).
Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w.
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1- Mol. weight
- 974.63 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNavitoclax ↗
- ChEMBLCHEMBL443684 ↗
Also known as
- abt263
- abt 263
- abt-263
- abt-263
- abt-263
- abt-263
- navitoclax
- navitoclax
- navitoclax
- navitoclax
- navitoclax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06210750 | Phase 2 | Aug 9, 2024 | National Cancer Institute (NCI), SWOG Cancer Research Network |
| NCT06007911 | Phase 1 | Feb 29, 2024 | Medical College of Wisconsin |
| NCT05740449 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2023 | Fight Kids Cancer, Humboldt University, Innovative Therapies For Children with Cancer Consortium, Princess Maxima Center for Pediatric Oncology |
| NCT05864742 | Phase 2 | Sep 7, 2023 | Peter MacCallum Cancer Centre |
| NCT05564650 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | AbbVie, Thomas Jefferson University |
| NCT05358639 | Phase 1 | Nov 9, 2022 | Exactis Innovation, Sunnybrook Health Sciences Centre, University of Montreal, University of Toronto |
| NCT05192889 | Phase 1/Phase 2 (Phase 2) | Aug 25, 2022 | AbbVie, St. Jude Children's Hospital |
| NCT05222984 | Phase 1 | Jul 29, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05455294 | Phase 1 | Jul 18, 2022 | AbbVie, Harvard University |
| NCT05054465 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2021 | Ben Gurion University, Hebrew University, Israeli Medical Association, Technion University, Tel Aviv University |
| NCT04472598 | Phase 3 | Sep 29, 2020 | AbbVie |
| NCT04468984 | Phase 3 | Aug 31, 2020 | AbbVie |
| NCT04454658 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2020 | AbbVie |
| NCT04480086 | Phase 1 | Jul 31, 2020 | AbbVie |
| NCT04041050 | Phase 1 | Aug 26, 2019 | AbbVie |
| NCT03366103 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2017 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT03222609 | Phase 2 | Oct 31, 2017 | AbbVie |
| NCT03181126 | Phase 1 | Aug 25, 2017 | AbbVie |
| NCT02520778 | Phase 1 | Mar 31, 2016 | Harvard University, National Cancer Institute (NCI) |
| NCT02591095 | Phase 2 | Jan 1, 2016 | ARCAGY-GINECO, French Cancer Research Hospital Program, University of Caen-Normandie |
Showing 20 of 45 trials
Page 1 / 3
Organizations
Research & Development (31)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 22 | 16 | 4 | 2006 |
| Genentech | For profit | 14 | 2 | 2 | 2007 |
| Abbott | For profit | 9 | 9 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 8 | 6 | 2 | 2013 |
| Harvard University | Academic/Hospital | 4 | 1 | 2 | 2013 |
| ARCAGY-GINECO | For profit | 1 | 0 | 1 | 2016 |
| Ben Gurion University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Exactis Innovation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Fight Kids Cancer | Academic/Hospital | 1 | 0 | 1 | 2023 |
| French Cancer Research Hospital Program | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Innovative Therapies For Children with Cancer Consortium | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Israeli Medical Association | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Princess Maxima Center for Pediatric Oncology | Academic/Hospital | 1 | 1 | 1 | 2023 |
31 organizations
Page 1 / 2